Last reviewed · How we verify

FT218 — Competitive Intelligence Brief

FT218 (FT218) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium oxybate (extended-release formulation). Area: Neurology.

phase 3 Sodium oxybate (extended-release formulation) GABA-B receptor (indirect mechanism via sodium oxybate metabolite) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

FT218 (FT218) — Avadel. FT218 is a long-acting formulation of sodium oxybate that provides extended-release delivery to treat narcolepsy and other sleep-wake disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FT218 TARGET FT218 Avadel phase 3 Sodium oxybate (extended-release formulation) GABA-B receptor (indirect mechanism via sodium oxybate metabolite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium oxybate (extended-release formulation) class)

  1. Avadel · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FT218 — Competitive Intelligence Brief. https://druglandscape.com/ci/ft218. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: